Skip to main content

Table 3 Summary table of differentiated allogeneic MSC in cartilage regeneration

From: Changes in immunological profile of allogeneic mesenchymal stem cells after differentiation: should we be concerned?

Paper Model In vitro immunogenicity In vitro immunosuppressive ability In vivo engraftment In vivo immune marker expression In vivo functional benefits In vivo cellular response In vivo antibody response
Ryan et al.[5] Allogeneic rat chondrogenically differentiated MSCs implanted subcutaneously Increased T-cell proliferation and activation. Increased susceptibility to allo-specific cytotoxic lysis. Granzyme B + CD8+ T cells generated against dMSCs Immunosuppressive ability lost after differentiation. PGE2 and NO secretion significantly reduced Extensive cellular infiltration leading to graft damage NT NT CD3+ and CD68+ immune cell infiltration. Local and systemic cellular memory response to dMSCs; this response only seen locally and without encapsulation in undifferentiated MSCs Increased anti-donor antibody levels. Th1 type antibody response
Zheng et al.[53] Human RA patients' T cells with allogeneic chondrogenically differentiated MSCs No collagen II-specific T-cell proliferation to dMSCs dMSCs could suppress allogeneic T-cell proliferation and activation. NT NT NT NT NT
dMSCs could suppress CD4+ and CD8+ inflammatory cytokine production.
dMSCs and undifferentiated MSCs secreted similar TGFβ1 levels
Technau et al.[55] In vitro assessment of human chondrogenically differentiated MSCs dMSCs stained positive for HLA-ABC and HLA-DR. NT NT NT NT NT NT
dMSCs secreted IFNγ
Chen et al.[54] In vitro assessment of rat chondrogenically differentiated MSCs Upregulation of CD80 and CD86 NT NT NT NT NT NT
  1. Data related to immunological profile of MSCs both in vitro and in vivo are collated. dMSC, differentiated mesenchymal stem cell; HLA-ABC, human leukocyte antigen ABC; HLA-DR, human leukocyte antigen DR; IFN-γ, interferon-γ; MSC, mesenchymal stem cell; NO, nitric oxide; NT, not tested; PGE2, prostaglandin E2; RA, rheumatoid arthritis; TGFβ1, transforming growth factor β1.